RxDoctor Payments DataLook up a doctor →

John Boone, MD

Rheumatology · Nashville, TNNPI 1578950044

Payments from drug & device makers

$69,911in general payments, 2019–2025

Across 874 payments — averaging $79.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$31K
  • Novartis$11K
  • AbbVie$8K
  • Janssen Scientific Affairs, LLC$6K
  • Amgen$6K
  • Johnson & Johnson$3K
  • plus $6K from 19 others

What the payments were for

  • Consulting fees$30,70144%
  • Speaking & faculty fees$16,95024%
  • Travel & lodging$3,7045%
  • Food & beverage$18,53627%
  • Education$200%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,911 in reported general payments places this provider in the 80th percentile of 127 rheumatology providers in Tennessee.

See all rheumatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,169,889
Medicare patients
422
Services billed
103,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab12$147,672
RinvoqUpadacitinib18$109,256
Enbrel SureclickEtanercept12$86,365
KineretAnakinra13$70,623
OtezlaApremilast12$58,906
OtrexupMethotrexate/Pf13$9,328
Colchicine48$5,676
MethotrexateMethotrexate Sodium185$5,480
Mycophenolate Mofetil22$3,260
Febuxostat17$2,882
Leflunomide21$2,311
Celecoxib51$2,069
Prednisone263$1,948
Hydroxychloroquine Sulfate57$1,740
Sulfasalazine DrSulfasalazine13$732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$7,648$109,25618 claims
AmgenOtezla$5,576$58,90612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 127 rheumatology providers in Tennessee.

Other rheumatology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →